Literature DB >> 11046096

Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.

Y A Kuryshev1, A M Brown, L Wang, C R Benedict, D Rampe.   

Abstract

Administration of the 5-hydroxytryptamine 3 receptor class of antiemetic agents has been associated with prolongation in the QRS, JT, and QT intervals of the ECG. To explore the mechanisms underlying these findings, we examined the effects of granisetron, ondansetron, dolasetron, and the active metabolite of dolasetron MDL 74,156 on the cloned human cardiac Na(+) channel hH1 and the human cardiac K(+) channel HERG and the slow delayed rectifier K(+) channel KvLQT1/minK. Using patch-clamp electrophysiology we found that all of the drugs blocked Na(+) channels in a frequency-dependent manner. At a frequency of 3 Hz, the IC(50) values for block of Na(+) current measured 2.6, 88.5, 38.0, and 8.5 microM for granisetron, ondansetron, dolasetron, and MDL 74,156, respectively. Block was relieved by strong hyperpolarizing potentials, suggesting a possible interaction with an inactivated channel state. Recovery from inactivation was impaired at -80 mV compared with -100 mV, and the fractional recovery was impaired by drug in a concentration-dependent manner. IC(50) values for block of the HERG cardiac K(+) channel measured 3.73, 0.81, 5.95, and 12.1 microM for granisetron, ondansetron, dolasetron, and MDL 74,156, respectively. Ondansetron (3 microM) also slowed decay of HERG tail currents. In contrast, none of these drugs (10 microM) produced greater than 30% block of the slow delayed rectifier K(+) channel KvLQT1/minK. We concluded that the antiemetic agents tested in this study block human cardiac Na(+) channels probably by interacting with the inactivated state. This may lead to clinically relevant Na(+) channel blockade, especially when high heart rates or depolarized/ischemic tissue is present. The submicromolar affinity of ondansetron for the HERG K(+) channel likely underlies the prolongation of cardiac repolarization reported for this drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046096

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  [Long QT syndrome].

Authors:  S Zbinden
Journal:  Anaesthesist       Date:  2006-09       Impact factor: 1.041

2.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

3.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

Review 4.  Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

5.  A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.

Authors:  Kenjiro Aogi; Hiroshi Sakai; Hirohisa Yoshizawa; Norikazu Masuda; Nobuyuki Katakami; Yasuhiro Yanagita; Kenichi Inoue; Masaru Kuranami; Mitsuhiro Mizutani; Noriyuki Masuda
Journal:  Support Care Cancer       Date:  2011-08-02       Impact factor: 3.603

Review 6.  Gastroparesis: Medical and Therapeutic Advances.

Authors:  Christopher M Navas; Nihal K Patel; Brian E Lacy
Journal:  Dig Dis Sci       Date:  2017-07-18       Impact factor: 3.199

Review 7.  Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?

Authors:  Tong J Gan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

Authors:  Dierk Thomas; Bettina C Hammerling; Kezhong Wu; Anna-Britt Wimmer; Eckhard K Ficker; Glenn E Kirsch; Mary C Kochan; Barbara A Wible; Eberhard P Scholz; Edgar Zitron; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

9.  The acute effect of tropisetron on ECG parameters in cancer patients.

Authors:  Ozlem Yavas; Mehmet Yazici; Onder Eren; Cem Boruban; Mehmet Artac; Mine Genc
Journal:  Support Care Cancer       Date:  2008-02-01       Impact factor: 3.603

10.  Ondansetron induced fatal ventricular tachycardia.

Authors:  R Chandrakala; C N Vijayashankara; Kushal K Kumar; N Sarala
Journal:  Indian J Pharmacol       Date:  2008-08       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.